AMERICAN BIOMED, Minimally Invasive Technology (ABMI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tom ablett who wrote (617)	5/2/1998 12:25:00 PM
From: Jeffrey L. Henken	Read Replies (1) of 2887

The sustained rise in volume in ABMI will very soon be confirmed by a sustained rise in the stock Tom. It's taken quite a while for the share price to catch up to the fundamental improvements that investors were aware of with American BioMed now let the real story unfold! American BioMed is more than just a silicone catheter company. The exciting products that have been waiting for validation in the form of FDA trials could be on the verge of really shining! The OmniCath should resume phase II testing soon. After it is approved for use as an atherectomy device it will be perhaps the most outstanding atherectomy device in this over $500 million a year market. americanbiomed.com The OmniStent designs are truly exciting, protected by American BioMed's patents and hopefully will be gearing up to start FDA trials this year. While almost every major company in the minimally invasive surgical field has new stent designs coming to market I remain convinced that the OmniStent will make it big in this rapidly growing market that represents the company's biggest market opportunity. americanbiomed.com The GuideWire MicroFilter is the only patented method of reducing the risk of a stroke or embolism after angioplasty that I am aware of in the minimally invasive surgical field. This market is also estimated to exceed $500 million a year. ISO 9001 certification along with upcoming CE Mark approval will very much add to the bottom line. FDA approval of four more versions of the bilumen catheters should happen soon. americanbiomed.com New distributors will be signing up soon to extend the companies world wide distribution system. 1998 will truly be the year for ABMI Shareholders! I think the next week or so will be when we finally see ABMI break out through the resistance to the upside! GO ABMI! Regards, Jeff

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next